Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tyco’s Respiratory Unit Receives Fourth FDA Warning Letter This Year

This article was originally published in The Gray Sheet

Executive Summary

Tyco Healthcare has received four warning letters from FDA citing quality systems deficiencies in its respiratory products division in the last eight months

You may also be interested in...



Earnings Calls In Brief

Tyco Healthcare: Firm plans to invest $15 mil.-$20 mil. to step up its regulatory and quality affairs programs, according to President Rich Meelia. During Tyco's earnings call Feb. 2, Meelia reported that the healthcare division has separated its quality assurance from regulatory affairs in an effort to "aggressively resolve" compliance issues plaguing the imaging and respiratory segments, which resulted in the receipt of four warning letters directed at the company in 2005 (1"The Gray Sheet" Oct. 10, 2005, p. 9). "We feel very confident in our fixes. The relationship and the interaction we've been having with the FDA has been extremely positive," Meelia said, noting that one warning letter already has been resolved. Regulatory issues reduced first quarter sales by $26 mil.; however, the firm expects sales growth to be back in the mid-single-digit range in the second half of 2006...

Earnings Calls In Brief

Tyco Healthcare: Firm plans to invest $15 mil.-$20 mil. to step up its regulatory and quality affairs programs, according to President Rich Meelia. During Tyco's earnings call Feb. 2, Meelia reported that the healthcare division has separated its quality assurance from regulatory affairs in an effort to "aggressively resolve" compliance issues plaguing the imaging and respiratory segments, which resulted in the receipt of four warning letters directed at the company in 2005 (1"The Gray Sheet" Oct. 10, 2005, p. 9). "We feel very confident in our fixes. The relationship and the interaction we've been having with the FDA has been extremely positive," Meelia said, noting that one warning letter already has been resolved. Regulatory issues reduced first quarter sales by $26 mil.; however, the firm expects sales growth to be back in the mid-single-digit range in the second half of 2006...

Tyco Healthcare Looks To New Acquisitions After Splitting From Parent

Tyco International maintains that its spin-off of Tyco Healthcare will allow the newly independent healthcare business to grow more rapidly

Related Content

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel